Cedar Fair and Insmed Set for Q4 Results Amid Post-Merger and Clinical Milestones
Investors are bracing for pivotal Q4 2025 earnings reports from amusement park giant Six Flags (Legacy Cedar Fair) and biotech firm Insmed. While Six Flags navigates the complexities of its recent mega-merger, Insmed is focused on the commercial scaling of its lead therapy and the regulatory path for its pipeline.